| Authors: |
Hinrichs MJM; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland. hinrichsm@medimmune.com., Ryan PM; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Zheng B; Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, Maryland., Afif-Rider S; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Yu XQ; Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, Maryland., Gunsior M; Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, Maryland., Zhong H; Oncology Research, MedImmune, Gaithersburg, Maryland., Harper J; Oncology Research, MedImmune, Gaithersburg, Maryland., Bezabeh B; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland., Vashisht K; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Rebelatto M; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Reed M; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Ryan PC; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland., Breen S; Oncology Research, MedImmune, Gaithersburg, Maryland., Patel N; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom., Chen C; Oncology Research, MedImmune, Gaithersburg, Maryland., Masterson L; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom., Tiberghien A; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom., Howard PW; Spirogen Ltd., QMB Innovation Centre, London, United Kingdom., Dimasi N; Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland., Dixit R; Biologics Safety Assessment, MedImmune, Gaithersburg, Maryland. |